Abstract
The synthesis and anti-Helicobacter pylori activity of a novel cephem derivative FR182024 (1) are described. FR182024 having a (5-methyl-1,3,4-thiadiazol-2-yl)-thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have extremely potent in vitro anti-H.pylori activity, superior therapeutic efficacy to AMPC and CAM, and low potential for causing diarrhea.
MeSH terms
-
Amoxicillin / pharmacology
-
Animals
-
Anti-Bacterial Agents / chemical synthesis*
-
Anti-Bacterial Agents / pharmacology
-
Carbapenems / chemical synthesis*
-
Carbapenems / pharmacology
-
Clarithromycin / pharmacology
-
Disease Models, Animal
-
Helicobacter pylori / drug effects*
-
Lactams*
-
Mice
-
Molecular Structure
-
beta-Lactamases / metabolism
-
beta-Lactams / chemical synthesis*
-
beta-Lactams / pharmacology
Substances
-
Anti-Bacterial Agents
-
Carbapenems
-
Lactams
-
beta-Lactams
-
Amoxicillin
-
FR 182024
-
beta-Lactamases
-
Clarithromycin